Allos Therapeutics, Inc. Release: Data Shows Activity of FOLOTYN(R) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Following Treatment with CHOP

LUGANO, Switzerland--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results from a retrospective analysis of data from the Company’s pivotal PROPEL trial, which assessed the safety and efficacy of single-agent FOLOTYN® (pralatrexate injection) as a second-line treatment in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who received CHOP as their first-line treatment. Data were presented at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 15-18).

Back to news